In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT.

The phosphatidylinositol 3-kinase/AKT signaling pathway plays a critical role in activating survival and antiapoptotic pathways within cancer cells. Several studies have shown that this pathway is constitutively activated in many different cancer types. The goal of this study was to discover novel compounds that bind to the pleckstrin homology (PH) domain of AKT, thereby inhibiting AKT activation. Using proprietary docking software, 22 potential PH domain inhibitors were identified. Surface plasmon resonance spectroscopy was used to measure the binding of the compounds to the expressed PH domain of AKT followed by an in vitro activity screen in Panc-1 and MiaPaCa-2 pancreatic cancer cell lines. We identified a novel chemical scaffold in several of the compounds that binds selectively to the PH domain of AKT, inducing a decrease in AKT activation and causing apoptosis at low micromolar concentrations. Structural modifications of the scaffold led to compounds with enhanced inhibitory activity in cells. One compound, 4-dodecyl-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide, inhibited AKT and its downstream targets in cells as well as in pancreatic cancer cell xenografts in immunocompromised mice; it also exhibited good antitumor activity. In summary, a pharmacophore for PH domain inhibitors targeting AKT function was developed. Computer-aided modeling, synthesis, and testing produced novel AKT PH domain inhibitors that exhibit promising preclinical properties.

[1]  P. Cohen,et al.  Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα , 1997, Current Biology.

[2]  S. Goodman,et al.  K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. , 1993, The American journal of pathology.

[3]  Andrius Kazlauskas,et al.  PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase , 1994, Nature.

[4]  Jennifer Skeen,et al.  Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. , 2003, Genes & development.

[5]  G. Powis,et al.  Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues. , 2003, Molecular cancer therapeutics.

[6]  S. Wright,et al.  NBD-TMA: a novel fluorescent substrate of the peritubular organic cation transporter of renal proximal tubules , 2000, Pflügers Archiv.

[7]  J. Wesselink,et al.  Molecular cloning, expression and characterization of the human serine/threonine kinase Akt-3. , 1999, European journal of biochemistry.

[8]  Jesse D. Martinez,et al.  Bile acid hydrophobicity is correlated with induction of apoptosis and/or growth arrest in HCT116 cells. , 2001, The Biochemical journal.

[9]  Lei Du-Cuny,et al.  Discovery of a novel class of AKT pleckstrin homology domain inhibitors , 2008, Molecular Cancer Therapeutics.

[10]  Spyro Mousses,et al.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.

[11]  S. Hewitt,et al.  Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt , 2006, Molecular Cancer Therapeutics.

[12]  G. Paine-Murrieta,et al.  Human tumor models in the severe combined immune deficient (scid) mouse , 1997, Cancer Chemotherapy and Pharmacology.

[13]  G. Semenza,et al.  Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. , 2000, Cancer research.

[14]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[15]  M. Hidalgo,et al.  Exploiting novel molecular targets in gastrointestinal cancers. , 2007, World journal of gastroenterology.

[16]  M. Montminy,et al.  CREB Is a Regulatory Target for the Protein Kinase Akt/PKB* , 1998, The Journal of Biological Chemistry.

[17]  Yiling Lu,et al.  Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.

[18]  N. C. Price,et al.  Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change. , 2003, The Biochemical journal.

[19]  S. R. Datta,et al.  Cellular survival: a play in three Akts. , 1999, Genes & development.

[20]  I. Kuntz,et al.  The maximal affinity of ligands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[21]  D R Alessi,et al.  Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo. , 1999, The Biochemical journal.

[22]  L. Cantley,et al.  New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P. Workman,et al.  Drugging the PI3 kinome , 2006, Nature Biotechnology.

[24]  J. Woodgett,et al.  Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. , 1998, The Biochemical journal.

[25]  R. Weissleder,et al.  Fate of a bioactive fluorescent wortmannin derivative in cells. , 2008, Bioconjugate chemistry.

[26]  J. Woodgett,et al.  Unravelling the activation mechanisms of protein kinase B/Akt , 2003, FEBS letters.

[27]  W. Liu,et al.  Up-regulation of Akt3 in Estrogen Receptor-deficient Breast Cancers and Androgen-independent Prostate Cancer Lines* , 1999, The Journal of Biological Chemistry.

[28]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[29]  G. Powis,et al.  In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. , 2004, Oncology research.

[30]  K. M. Nicholson,et al.  The protein kinase B/Akt signalling pathway in human malignancy. , 2002, Cellular signalling.

[31]  Nathan A. Baker,et al.  PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations , 2004, Nucleic Acids Res..

[32]  B. Burgering,et al.  Essential Role for Protein Kinase B (PKB) in Insulin-induced Glycogen Synthase Kinase 3 Inactivation , 1998, The Journal of Biological Chemistry.

[33]  C. E. Peishoff,et al.  A critical assessment of docking programs and scoring functions. , 2006, Journal of medicinal chemistry.

[34]  W. Wahli,et al.  Dosage-Dependent Effects of Akt1/Protein Kinase Bα (PKBα) and Akt3/PKBγ on Thymus, Skin, and Cardiovascular and Nervous System Development in Mice , 2005, Molecular and Cellular Biology.

[35]  Maria Deak,et al.  High-Resolution Structure of the Pleckstrin Homology Domain of Protein Kinase B/Akt Bound to Phosphatidylinositol (3,4,5)-Trisphosphate , 2002, Current Biology.

[36]  I. Campbell,et al.  The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. , 2001, Cancer research.

[37]  M. Rebecchi,et al.  Pleckstrin homology domains: a common fold with diverse functions. , 1998, Annual review of biophysics and biomolecular structure.

[38]  Qun Li.  Recent progress in the discovery of Akt inhibitors as anticancer agents , 2007 .

[39]  C. Roumestand,et al.  Inhibition of Akt Kinase Activity by a Peptide Spanning the βA Strand of the Proto-oncogene TCL1* , 2004, Journal of Biological Chemistry.